Elahe Mostaghel, M.D., Ph.D.

Elahe Mostaghel M.D., Ph.D.
faculty member

Elahe Mostaghel, M.D., Ph.D.

Associate Member
Clinical Research Division, Fred Hutch

Mailstop: D5-380

Dr. Elahe Mostaghel studies how prostate cancer becomes resistant to therapies that deprive tumors of androgen hormones, such as testosterone, and she is developing new drugs to target them. Androgens act as a fuel for prostate tumors. The first-line treatment for advanced prostate cancer is androgen-deprivation therapy, which shrinks the tumors — but only for a time. She is learning how these prostate tumors begin producing their own androgens, rendering these drugs ineffective. Dr. Mostagel studies the genetic signatures of resistant tumors that may make them vulnerable to new forms of treatment. Using this knowledge, she is developing new personalized medicine approaches for treating men with advanced, treatment-resistant prostate tumors.

Other Appointments & Affiliations

Clinician Investigator
VA Puget Sound Health Care System

Associate Professor, Medical Oncology Division
University of Washington School of Medicine

Education

M.D., Duke University, 2000

Ph.D., Duke University, 1999

B.A., Harvard University, 1992

Research Interests

Research is focused on the pathways of intra-tumoral androgen steroidogenesis and metabolism, structural alterations in the androgen receptor, the activity of androgen transport proteins, and how alterations in these and other pathways may influence the sequencing of androgen and chemotherapy treatments. An important goal is to determine how patient and tumor-specific alterations in these proteins may be used to predict response to agents targeting these pathways.

Recent Projects

Determining and exploiting mechanisms of AR-mediated suppression of cell proliferation and survival

Identifying druggable modulators of response to high-dose testosterone treatment

Preclinical studies: Activity of novel Sigma1 inhibitors in the LuCaP prostate cancer xenograft models

Steroid transport proteins in castration resistant prostate cancer

Looking beyond CYP17A: optimizing next-generation steroid-synthesis inhibition in castration resistant prostate cancer

Exploiting mechanisms of response and resistance to next generation androgen pathway antagonists

Pharmacogenetic determinants of intratumoral abiraterone exposure

Exploiting synergy to optimize taxane sensitivity in prostate cancer

Toward the practice of precision medicine: a biomarker validation coordinating center

 

spotlight

"We're going to get better about our understanding of cancer therapy and how to target it. … That's the future.”

 —Dr. Elahe Mostaghel

Find A Clinical Trial

For the Media

The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.

Email media@fredhutch.org or call 206.667.2210